Allarity Therapeutics Unveils New Stenoparib Data at AACR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy ALLR?
Source: NASDAQ.COM
- Clinical Trial Results: Allarity Therapeutics presented Phase 2 trial data for Stenoparib in recurrent ovarian cancer at the AACR Annual Meeting, revealing that patients with high DPR scores experienced significantly improved overall survival, underscoring the importance of DPR-based patient selection in treatment efficacy.
- Preclinical Research Findings: The second poster highlighted Stenoparib's ability to block the WNT/β-catenin signaling pathway and inhibit the growth of colorectal cancer cell lines at clinically relevant concentrations, emphasizing a significant unmet medical need in this area.
- Innovative Drug Mechanism: Stenoparib, an orally available small-molecule inhibitor targeting both PARP and tankyrase, offers a differentiated treatment approach by combining DNA repair inhibition with WNT pathway modulation, with Allarity holding exclusive global rights for its development and commercialization.
- Market Performance Review: ALLR's stock has traded between $0.76 and $2.35 over the past year, closing at $1.38 on Wednesday with a 10.40% increase, indicating positive market sentiment regarding its clinical advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALLR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALLR
Wall Street analysts forecast ALLR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.550
Low
9.50
Averages
9.50
High
9.50
Current: 1.550
Low
9.50
Averages
9.50
High
9.50
About ALLR
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Allarity Therapeutics Unveils New Stenoparib Data at AACR 2026
- Clinical Trial Results: Allarity Therapeutics presented Phase 2 trial data for Stenoparib in recurrent ovarian cancer at the AACR Annual Meeting, revealing that patients with high DPR scores experienced significantly improved overall survival, underscoring the importance of DPR-based patient selection in treatment efficacy.
- Preclinical Research Findings: The second poster highlighted Stenoparib's ability to block the WNT/β-catenin signaling pathway and inhibit the growth of colorectal cancer cell lines at clinically relevant concentrations, emphasizing a significant unmet medical need in this area.
- Innovative Drug Mechanism: Stenoparib, an orally available small-molecule inhibitor targeting both PARP and tankyrase, offers a differentiated treatment approach by combining DNA repair inhibition with WNT pathway modulation, with Allarity holding exclusive global rights for its development and commercialization.
- Market Performance Review: ALLR's stock has traded between $0.76 and $2.35 over the past year, closing at $1.38 on Wednesday with a 10.40% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Allarity Therapeutics 2025 Financial Overview
- Revenue Performance: Allarity Therapeutics reported FY 2025 revenue of $0.32 million, indicating ongoing challenges in the market, as the revenue remains insufficient for achieving a sustainable profit level.
- Net Loss Improvement: The net loss attributable to shareholders for 2025 was $11.2 million, a decrease from $25.1 million in 2024, suggesting some progress in cost control and operational optimization.
- Financial Health Status: Despite the reduction in net loss, the company must demonstrate stronger revenue growth in future financial reports to attract investors and improve market confidence.
- Market Outlook: Allarity Therapeutics faces the challenge of effectively transforming its business model to achieve sustainable revenue growth and profitability, particularly in the highly competitive biopharmaceutical industry.
See More
Allarity Therapeutics Secures $20 Million Financing to Advance Cancer Treatment
- Successful Financing: Allarity Therapeutics announced the closure of a $20 million non-convertible debt financing with Streeterville Capital, aimed at accelerating the development of its lead candidate, Stenoparib, and extending its cash runway into mid-2028.
- Clinical Trial Advancement: The financing will support the completion of the ongoing Phase 2 ovarian cancer trial, prepare for pivotal development, and advance the company's Drug Response Predictor (DRP) companion diagnostic platform, enhancing its competitive position in the market.
- Significant Drug Potential: Stenoparib has demonstrated durable clinical benefits in heavily pre-treated ovarian cancer patients, with some remaining on therapy for over 30 months, and its dual mechanism design offers potential applications across multiple cancer types.
- Stock Price Surge: Following the financing announcement, ALLR shares surged by 21%, with an additional 3.23% increase in the subsequent trading session, reflecting positive market expectations for the company's future developments.
See More
Allarity Secures $20 Million Financing to Extend Cash Runway
- Financing Scale and Structure: Allarity Therapeutics has closed a $20 million non-convertible debt financing, comprising a $10.93 million promissory note and a $10 million secured note, which will extend the company's cash runway into summer 2028, ensuring ongoing operations in clinical trials.
- Clinical Trial Advancement: The financing will primarily support the acceleration of stenoparib's pivotal development, facilitate preparations for the FDA meeting, and advance the companion diagnostic strategy, thereby paving the way for the drug's commercialization and enhancing the company's market competitiveness in oncology.
- Clinical Data Potential: In ongoing clinical trials, stenoparib has demonstrated durable clinical benefits in heavily pre-treated ovarian cancer patients, with some patients remaining on therapy for over 30 months, indicating the long-term therapeutic potential of the drug in this population.
- Strategic Development Direction: Allarity plans to leverage this financing to further advance its DRP companion diagnostic platform and explore potential applications in other WNT-driven tumor types, reflecting the company's ongoing commitment to innovative therapeutic solutions.
See More
Allarity Therapeutics Advances Stenoparib with FDA Fast Track Designation
- Strategic Reset: Over the past two years, Allarity has focused on developing the dual-target inhibitor stenoparib, which has recently received FDA Fast Track Designation, marking a significant advancement in the treatment of ovarian cancer and expected to enhance market competitiveness.
- Clinical Outcomes: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival has not yet been reached, with follow-up exceeding 22 months, indicating the durability and efficacy of stenoparib, which could attract higher investment interest.
- New Indication Expansion: Allarity has begun exploring stenoparib's application in recurrent Small Cell Lung Cancer, signing a fully funded clinical trial agreement with the US Veteran's Administration, further broadening its market potential.
- Financial Stability: The company has strengthened its financial foundation by simplifying its capital structure, ensuring continued access to public markets, which is expected to provide robust support for future clinical development.
See More
Allarity Therapeutics CEO Letter Highlights Progress Toward Stenoparib FDA Approval
- Strategic Reset: In 2024, Allarity undertook a strategic reset by focusing exclusively on stenoparib and shedding low-value programs, which enhanced its potential to treat complex cancers and laid a solid foundation for future clinical and regulatory success.
- Clinical Progress: In 2025, Allarity accelerated the FDA approval process for stenoparib while expanding its clinical potential into high-value indications like recurrent Small Cell Lung Cancer, further strengthening the company's financial health.
- Clinical Data: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival had not been reached, with some patients on therapy for over 30 months, underscoring stenoparib's tolerability and clinical benefit, thus supporting its advantages as a next-generation PARP inhibitor.
- Future Outlook: Looking ahead to 2026, Allarity plans to expedite the approval process for stenoparib and explore its applications in other cancer indications, aiming to enhance enterprise value and address significant unmet medical needs.
See More
Allarity Therapeutics Unveils New Stenoparib Data at AACR 2026
- Clinical Trial Results: Allarity Therapeutics presented Phase 2 trial data for Stenoparib in recurrent ovarian cancer at the AACR Annual Meeting, revealing that patients with high DPR scores experienced significantly improved overall survival, underscoring the importance of DPR-based patient selection in treatment efficacy.
- Preclinical Research Findings: The second poster highlighted Stenoparib's ability to block the WNT/β-catenin signaling pathway and inhibit the growth of colorectal cancer cell lines at clinically relevant concentrations, emphasizing a significant unmet medical need in this area.
- Innovative Drug Mechanism: Stenoparib, an orally available small-molecule inhibitor targeting both PARP and tankyrase, offers a differentiated treatment approach by combining DNA repair inhibition with WNT pathway modulation, with Allarity holding exclusive global rights for its development and commercialization.
- Market Performance Review: ALLR's stock has traded between $0.76 and $2.35 over the past year, closing at $1.38 on Wednesday with a 10.40% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Allarity Therapeutics 2025 Financial Overview
- Revenue Performance: Allarity Therapeutics reported FY 2025 revenue of $0.32 million, indicating ongoing challenges in the market, as the revenue remains insufficient for achieving a sustainable profit level.
- Net Loss Improvement: The net loss attributable to shareholders for 2025 was $11.2 million, a decrease from $25.1 million in 2024, suggesting some progress in cost control and operational optimization.
- Financial Health Status: Despite the reduction in net loss, the company must demonstrate stronger revenue growth in future financial reports to attract investors and improve market confidence.
- Market Outlook: Allarity Therapeutics faces the challenge of effectively transforming its business model to achieve sustainable revenue growth and profitability, particularly in the highly competitive biopharmaceutical industry.
See More
Allarity Therapeutics Secures $20 Million Financing to Advance Cancer Treatment
- Successful Financing: Allarity Therapeutics announced the closure of a $20 million non-convertible debt financing with Streeterville Capital, aimed at accelerating the development of its lead candidate, Stenoparib, and extending its cash runway into mid-2028.
- Clinical Trial Advancement: The financing will support the completion of the ongoing Phase 2 ovarian cancer trial, prepare for pivotal development, and advance the company's Drug Response Predictor (DRP) companion diagnostic platform, enhancing its competitive position in the market.
- Significant Drug Potential: Stenoparib has demonstrated durable clinical benefits in heavily pre-treated ovarian cancer patients, with some remaining on therapy for over 30 months, and its dual mechanism design offers potential applications across multiple cancer types.
- Stock Price Surge: Following the financing announcement, ALLR shares surged by 21%, with an additional 3.23% increase in the subsequent trading session, reflecting positive market expectations for the company's future developments.
See More
Allarity Secures $20 Million Financing to Extend Cash Runway
- Financing Scale and Structure: Allarity Therapeutics has closed a $20 million non-convertible debt financing, comprising a $10.93 million promissory note and a $10 million secured note, which will extend the company's cash runway into summer 2028, ensuring ongoing operations in clinical trials.
- Clinical Trial Advancement: The financing will primarily support the acceleration of stenoparib's pivotal development, facilitate preparations for the FDA meeting, and advance the companion diagnostic strategy, thereby paving the way for the drug's commercialization and enhancing the company's market competitiveness in oncology.
- Clinical Data Potential: In ongoing clinical trials, stenoparib has demonstrated durable clinical benefits in heavily pre-treated ovarian cancer patients, with some patients remaining on therapy for over 30 months, indicating the long-term therapeutic potential of the drug in this population.
- Strategic Development Direction: Allarity plans to leverage this financing to further advance its DRP companion diagnostic platform and explore potential applications in other WNT-driven tumor types, reflecting the company's ongoing commitment to innovative therapeutic solutions.
See More
Allarity Therapeutics Advances Stenoparib with FDA Fast Track Designation
- Strategic Reset: Over the past two years, Allarity has focused on developing the dual-target inhibitor stenoparib, which has recently received FDA Fast Track Designation, marking a significant advancement in the treatment of ovarian cancer and expected to enhance market competitiveness.
- Clinical Outcomes: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival has not yet been reached, with follow-up exceeding 22 months, indicating the durability and efficacy of stenoparib, which could attract higher investment interest.
- New Indication Expansion: Allarity has begun exploring stenoparib's application in recurrent Small Cell Lung Cancer, signing a fully funded clinical trial agreement with the US Veteran's Administration, further broadening its market potential.
- Financial Stability: The company has strengthened its financial foundation by simplifying its capital structure, ensuring continued access to public markets, which is expected to provide robust support for future clinical development.
See More
Allarity Therapeutics CEO Letter Highlights Progress Toward Stenoparib FDA Approval
- Strategic Reset: In 2024, Allarity undertook a strategic reset by focusing exclusively on stenoparib and shedding low-value programs, which enhanced its potential to treat complex cancers and laid a solid foundation for future clinical and regulatory success.
- Clinical Progress: In 2025, Allarity accelerated the FDA approval process for stenoparib while expanding its clinical potential into high-value indications like recurrent Small Cell Lung Cancer, further strengthening the company's financial health.
- Clinical Data: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival had not been reached, with some patients on therapy for over 30 months, underscoring stenoparib's tolerability and clinical benefit, thus supporting its advantages as a next-generation PARP inhibitor.
- Future Outlook: Looking ahead to 2026, Allarity plans to expedite the approval process for stenoparib and explore its applications in other cancer indications, aiming to enhance enterprise value and address significant unmet medical needs.
See More
